The use of inflammation by tumor cells

Cancer

Volumn 104, Issue 2, 2005, Pages 223-228

  Arias, Jose Ignacio ^a   Aller, María Angeles ^b   Arias, Jaime ^b  

^a HOSPITAL MONTE NARANCO   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHEMOKINE; COLONY STIMULATING FACTOR 1; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

ANGIOGENESIS; CACHEXIA; CANCER CELL; CARCINOGENESIS; CATABOLISM; CELL FUNCTION; CELL GROWTH; CELL INVASION; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; HYPOXIA; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY CELL; ISCHEMIA; LEUKOCYTE; MACROPHAGE; METASTASIS; MONOCYTE; NOTE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; REPERFUSION INJURY; REVASCULARIZATION; TISSUE REPAIR; TUMOR CELL;

CELL HYPOXIA; CELL PROLIFERATION; CHEMOKINES; ENDOCRINE SYSTEM; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVOUS SYSTEM PHYSIOLOGY; OXIDATIVE STRESS; WOUND HEALING;

EID: 22244432800     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21165     Document Type: Note

References (44)

1. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003;83:337-376.
2. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524-6536.
3. Ribatti D, Vacca A, Dammacco F. New non-angiogenesis dependent pathways for tumor growth. Eur J Cancer. 2003; 39:1835-1841.
4. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-1659.
5. Arya M, Patel HRH, Williamson M. Chemokines: key players in cancer. Curr Med Res Opin. 2003;19:557-564.
6. Aller MA, Arias JL, Lorente L, Nava MP, Duran HJ, Arias J. Neuro-immune-endocrine functional system and vascular pathology. Med Hypotheses. 2001;57:561-569.
7. Aller MA, Arias JL, Nava MP, Arias J. Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune and endocrine functional systems. Exp Biol Med. 2004;229:170-181.
8. Aller MA, Arias JL, Arias J. Inflammatory response phases and their hypothetical trophic meaning [letter]. Eur Resp J. 2004;23:353-354.
9. Aller MA, Arias JL, Arias J. Post-traumatic inflammatory response: perhaps a succession of phases with a nutritional purpose. Med Hypotheses. 2004;63:42-46.
10. Aller MA, Arias JL, Nava MP, Arias J. Evolutive trophic phases of the systemic acute inflammatory response, oxygen use mechanisms and metamorphosis. Psicothema, 2004;16: 369-372.
11. Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003;22:5907-5914.
12. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets. 2003;3:391-405.
13. Bamias A, Dimopoulos MA. Angiogenesis in human cancer: implications in cancer therapy. Eur J Intern Med. 2003;14: 459-469.
14. Sivridis E, Giatromanolaki A, Koukourakis MI. The vascular network of tumors-what is it for? J Pathol. 2003;201:173-180.
15. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000;36:1649-1660.
16. Mc Cord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159-163.
17. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 2002;13: 413-421.
18. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
19. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727-740.
20. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004;92:13-27.
21. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8:3137-3145.
22. Pawelec G. Tumor escape: antitumor effectors too much of a good thing? Cancer Immunol Immunother. 2004;53:262-274.
23. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol. 2003;532:91-107.
24. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol. 2003;200:465-470.
25. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
26. Pepper MS, Skobe M. Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol. 2003; 163:209-213.
27. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer. 2003;98:413-423.
28. Skobe M, Hawighorst J, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198.
29. 2A receptors. Annu Rev Immunol. 2004;22:21.1-21,26.
30. Borregaard N, Herlin T. Energy metabolism of human neutrophils during phagocytosis. J Clin Invest. 1982;70:550-557.
31. Naresh NK, Nerurkar AY, Borges AM. Angiogenesis is a redundant for tumour growth in lymph node metastases. Histopathology. 2001;38:466-470.
32. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA. 2003;100:7737-7742.
33. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-573.
34. Shevde LA, Welch DR. Metastasis suppressor pathways-an evolving paradigm. Cancer Lett. 2003;198:1-20.
35. Bamias A, Dimipoulos MA. Angiogenesis in human cancer: implications in cancer therapy. Eur J Intern Med. 2003;14: 459-469.
36. Fossati G, Moulding DA, Spiller DG, Moots RJ, White MR, Edward SW. The mitochondrial network of human neutrophils: role in chemotaxis, phagocytosis, respiratory burst activation and commitment to apoptosis. J Immunol. 2003; 170:1964-1972.
37. Toi M. Proinflammation in human tumor microenvironment: its status and implication. Med Sci Monit. 2002;8;25-26.
38. Crown AL, Cottle K, Lightman SL, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxford). 2002;56:723-733.
39. Tisdale MJ. The "cancer cachectic factor." Support Care Cancer. 2003;11:73-78.
40. Martignoni ME, Kunze P, Friess H. Cancer cachexia [abstract]. Molecular Cancer. 2003;2:36.
41. Guirao X. Impact of the inflammatory reaction on intermediary metabolism and nutrition status. Nutrition. 2002;18: 949-952.
42. Gospodarowicz M, O'Sullivan B. Prognostic factors in cancer. Semin Surg Oncol. 2003;21:13-18.
43. Nakamura H, Hase A. Cellular differentiation in the process of generation of the eukaryotic cell. Orig Life Evol Biosph. 1990/1991;20:499-514.
44. Guest JR. The Leeuwenhoek Lecture, 1995. Adaptation to life without oxygen. Phil Trans R Soc London B Biol Sci. 1995; 350:189-202.